NASDAQ:PETXAratana Therapeutics Stock Price, Forecast & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Aratana Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $4.92 0.00 (0.00 %) (As of 07/18/2019) Add Compare Share Today's Range$4.92Now: $4.92▼$4.9250-Day Range$4.92MA: $4.92▼$4.9252-Week Range$3.30Now: $4.92▼$7.16VolumeN/AAverage Volume1.03 million shsMarket Capitalization$241.08 millionP/E RatioN/ADividend YieldN/ABeta1.4 ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Aratana Therapeutics, Inc., a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States. Its product portfolio includes small molecule therapeutics and therapeutic candidates. The company markets NOCITA, a post-operative analgesia for cranial cruciate ligament surgery in dogs; ENTYCE for appetite stimulation in dogs; GALLIPRANT for the control of pain and inflammation associated with osteoarthritis in dogs; and canine osteosarcoma vaccine, live listeria vector for the treatment of dogs diagnosed with osteosarcoma in the United States. It is also developing NOCITA, a bupivacaine liposome injectable suspension for post-operative pain in cats; AT-002, a specific formulation of capromorelin for use in cats; AT-018, an oral CRTH2 antagonist for the treatment of atopic dermatitis in dogs; AT-006, an anti-viral eprociclovir that is used for the treatment of feline herpes virus-induced ophthalmic conditions in cats; AT-016, allogeneic adipose-derived stem cells for dogs; and AT-019, an EP4 receptor antagonist therapeutic candidate with potential in pain, inflammation, and other indications. In addition, the company develops AT-008, a therapeutic candidate for treating canine lymphoma in dogs; and other therapeutics for dogs and cats in Europe. It has collaboration agreement with Elanco Animal Health, Inc. to develop, manufacture, and commercialize GRAPIPRANT products; Pacira Pharmaceuticals, Inc. to develop and commercialization of licensed animal health products for NOCITA; and AskAt Inc for the development and commercialization of compound AT-019. Aratana Therapeutics, Inc. was founded in 2010 and is headquartered in Leawood, Kansas.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Aratana Therapeutics. Previous Next 3.0 Community Rank Outperform VotesAratana Therapeutics has received 409 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAratana Therapeutics has received 284 “underperform” votes. (Add your “underperform” vote.)Community SentimentAratana Therapeutics has received 59.02% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Aratana Therapeutics and other stocks. Vote “Outperform” if you believe PETX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PETX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAratana Therapeutics does not currently pay a dividend.Dividend GrowthAratana Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aratana Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.30% of the stock of Aratana Therapeutics is held by insiders.Percentage Held by Institutions65.00% of the stock of Aratana Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Aratana Therapeutics are expected to grow in the coming year, from ($0.29) to ($0.06) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aratana Therapeutics is -15.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aratana Therapeutics is -15.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAratana Therapeutics has a P/B Ratio of 2.38. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.93 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PETX Previous Symbol CUSIPN/A CIK1509190 Webwww.aratana.com Phone913-353-1000Debt Debt-to-Equity RatioN/A Current Ratio6.66 Quick Ratio5.32Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$35.41 million Price / Sales6.81 Cash FlowN/A Price / Cash FlowN/A Book Value$2.07 per share Price / Book2.38Profitability EPS (Most Recent Fiscal Year)($0.32) Net Income$-14,720,000.00 Net Margins-33.47% Return on Equity-12.99% Return on Assets-10.82%Miscellaneous Employees83 Outstanding Shares49,000,000Market Cap$241.08 million Next Earnings DateN/A OptionableOptionable Receive PETX News and Ratings via Email Sign-up to receive the latest news and ratings for PETX and its competitors with MarketBeat's FREE daily newsletter. Aratana Therapeutics (NASDAQ:PETX) Frequently Asked Questions How were Aratana Therapeutics' earnings last quarter? Aratana Therapeutics Inc (NASDAQ:PETX) issued its quarterly earnings data on Thursday, November, 1st. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.16) by $0.03. The biopharmaceutical company earned $21.56 million during the quarter, compared to the consensus estimate of $5.70 million. Aratana Therapeutics had a negative net margin of 33.47% and a negative return on equity of 12.99%. View Aratana Therapeutics' earnings history. Has Aratana Therapeutics been receiving favorable news coverage? Media stories about PETX stock have been trending positive on Wednesday, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Aratana Therapeutics earned a media sentiment score of 2.5 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news aboutAratana Therapeutics. Who are some of Aratana Therapeutics' key competitors? Some companies that are related to Aratana Therapeutics include BioXcel Therapeutics (BTAI), NextCure (NXTC), Endo International (ENDP), Rhythm Pharmaceuticals (RYTM), Athenex (ATNX), Amphastar Pharmaceuticals (AMPH), ImmunoGen (IMGN), Cue Biopharma (CUE), Omeros (OMER), Passage Bio (ORIC), Collegium Pharmaceutical (COLL), Kura Oncology (KURA), Gossamer Bio (GOSS), Nabriva Therapeutics (NBRV) and Cara Therapeutics (CARA). View all competitors. What other stocks do shareholders of Aratana Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aratana Therapeutics investors own include Celldex Therapeutics (CLDX), Synergy Pharmaceuticals (SGYP), Corcept Therapeutics (CORT), Pieris Pharmaceuticals (PIRS), Exelixis (EXEL), ACADIA Pharmaceuticals (ACAD), Corbus Pharmaceuticals (CRBP), Advaxis (ADXS), Aurinia Pharmaceuticals (AUPH) and Progenics Pharmaceuticals (PGNX). Who are Aratana Therapeutics' key executives? Aratana Therapeutics' management team includes the following people: Mr. Craig A. Tooman, Pres, CEO & Board Director (Age 53)Ms. Rhonda L. Hellums, CFO & Treasurer (Age 47)Mr. John C. Ayres J.D., VP of Corp. Devel. and Admin., Gen. Counsel & Sec. (Age 40)Mr. Brent A. Standridge, Consultant (Age 61)Ms. Rachel Reiff, Head of Corp. Communications What is Aratana Therapeutics' stock symbol? Aratana Therapeutics trades on the NASDAQ under the ticker symbol "PETX." What is Aratana Therapeutics' stock price today? One share of PETX stock can currently be purchased for approximately $4.92. How big of a company is Aratana Therapeutics? Aratana Therapeutics has a market capitalization of $241.08 million and generates $35.41 million in revenue each year. The biopharmaceutical company earns $-14,720,000.00 in net income (profit) each year or ($0.32) on an earnings per share basis. Aratana Therapeutics employs 83 workers across the globe. What is Aratana Therapeutics' official website? The official website for Aratana Therapeutics is www.aratana.com. How can I contact Aratana Therapeutics? Aratana Therapeutics' mailing address is 11400 TOMAHAWK CREEK PARKWAY SUITE 340, LEAWOOD KS, 66211. The biopharmaceutical company can be reached via phone at 913-353-1000 or via email at [email protected] This page was last updated on 5/27/2020 by MarketBeat.com Staff
